SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : DYAX: Dyax Corp. -- Ignore unavailable to you. Want to Upgrade?


To: keokalani'nui who wrote (2)1/22/2001 1:33:46 PM
From: keokalani'nui  Read Replies (2) | Respond to of 197
 
New developments in Phage.

doubletwist.com



To: keokalani'nui who wrote (2)6/5/2001 5:25:37 PM
From: nigel bates  Read Replies (2) | Respond to of 197
 
United States Patent 5,837,500
Ladner ,   et al. November 17, 1998
------------------------------------------------------------------------
Directed evolution of novel binding proteins
Abstract
In order to obtain a novel binding protein against a chosen target, DNA molecules, each encoding a protein comprising one of a family of similar potential binding domains and a structural signal calling for the display of the protein on the outer surface of a chosen bacterial cell, bacterial spore or phage (genetic package) are introduced into a genetic package. The protein is expressed and the potential binding domain is displayed on the outer surface of the package. The cells or viruses bearing the binding domains which recognize the target molecule are isolated and amplified. The successful binding domains are then characterized. One or more of these successful binding domains is used as a model for the design of a new family of potential binding domains, and the process is repeated until a novel binding domain having a desired affinity for the target molecule is obtained. In one embodiment, the first family of potential binding domains is related to bovine pancreatic trypsin inhibitor, the genetic package is M13 phage, and the protein includes the outer surface transport signal of the M13 gene III protein.
Inventors: Ladner; Robert Charles (Ijamsville, MD); Gutterman; Sonia Kosow (Belmont, MA); Roberts; Bruce Lindsay (Milford, MA); Markland; William (Milford, MA); Ley; Arthur Charles (Newton, MA); Kent; Rachel Baribault (Boxborough, MA)
Assignee: Dyax, Corp. (Cambridge, MA)
Appl. No.: 415922
Filed: April 3, 1995
...This application is is a continuation of Ladner, Guterman, Roberts, Markland, Ley and Kent, Ser. No. 08/009,319, filed Jan. 26, 1993, now patented, which is a division of Ladner, et al., Ser. No. 07/664,989, filed Mar. 1, 1991, now patented (U.S. Pat. No. 5,223,409; issued Jan. 9, 1993), which is a continuation-in-part of Ladner, Guterman, Roberts, and Markland, Ser. No. 07/487,063, filed Mar. 2, 1990, now abandoned, which is a continuation-in-part of Ladner and Guterman, Ser. No. 07/240,160, filed Sep. 2, 1988, now abandoned. Ser. No. 07/487,063 claimed priority under 35 U.S.C. 119 from PCT Application No. PCT/US89/03731, filed Sep. 1, 1989. All of the foregoing applications are hereby incorporated by reference...

164.195.100.11

(edit)

(previous patent no.s are 5,571,698; 5,403,484; 5,223,409 )